Abstract

Purpose Minimally invasive (MI) approaches for left ventricular assist device (LVAD) implantation has the potential to offer similar benefits to of other well-established cardiac surgery procedures. We performed a systematic review and meta-analysis to determine the potential benefits of MI LVAD implantation compared to sternotomy. Methods We searched MEDLINE and EMBASE databases for studies comparing MI continuous-flow LVAD implantation with sternotomy. Data was extracted by two independent investigators. The main outcomes were perioperative mortality and complications. Results 19 observational studies (1619 patients) with mean follow-up of 9 months were included. HeartWare was the most commonly implanted device (80%), followed by HeartMate II (6%). Serum bilirubin was lower (MD: -5.4 uM; 95%CI: ‒8.1 to -2.7; p Conclusion MI LVAD implantation led to an improved perioperative complication profile and enhanced patient recovery, potentially decreasing mid-term mortality. These are consistent with findings from other well-established MI cardiac surgical procedures. A future randomized trial could further clarify these benefits and establish this technique as a standard practice.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.